Bayesian Capital Management’s Precigen PGEN Stock Holding History

Bayesian Capital Management’s Portfolio PGEN Stock Details PGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-39,600	Closed	-$153K	–	288
2026 Q1	$153K	Buy	+39,600	New	+$162K	0.19%	123
2024 Q1	–	Sell	-11,300	Closed	-$15.1K	–	1037
2023 Q4	$15.1K	Buy	+11,300	New	+$13.3K	﹤0.01%	699
2022 Q4	–	Sell	-10,100	Closed	-$21K	–	975
2022 Q3	$21K	Sell	10,100 -5,500	-35%	-$11.6K	﹤0.01%	643
2022 Q2	$21K	Buy	+15,600	New	+$23.1K	﹤0.01%	732
2018 Q3	–	Sell	-11,700	Closed	-$163K	–	760
2018 Q2	$163K	Sell	11,700 -3,700	-24%	-$62.5K	0.04%	540
2018 Q1	$236K	Buy	+15,400	New	+$220K	0.06%	459
2017 Q3	–	Sell	-12,400	Closed	-$299K	–	606
2017 Q2	$299K	Buy	+12,400	New	+$272K	0.11%	289

Other funds holding PGEN

PCM

Patient Capital Management Baltimore, Maryland $3.05B AUM 42.09% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bayesian Capital Management's PGEN Position: Q2 2026 in Review

Bayesian Capital Management sold out of Precigen (PGEN) in Q2 2026, closing a stake of 39,600 shares — an estimated $153K sold.

Bayesian Capital Management first reported a position in PGEN in Q2 2017 and held it in 7 quarters. The position peaked at $299K in Q2 2017. 210 funds tracked by Wall St. Rank hold PGEN as of Q2 2026.

Bayesian Capital Management reported no remaining Precigen position as of Q2 2026 after selling out during the quarter.
Bayesian Capital Management sold 39,600 Precigen shares in Q2 2026, an estimated $153K.
Bayesian Capital Management first reported a position in Precigen in Q2 2017 and held it in 7 quarters.
Bayesian Capital Management's Precigen position peaked at $299K in Q2 2017.
210 funds tracked by Wall St. Rank held Precigen as of Q2 2026.

Based on Bayesian Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.